Driving Breakthroughs in Healthcare, One Bold Idea at a Time

Featured

Genesys Capital is closing its largest fund to date – Genesys Ventures IV LP

Latest

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

11 December 2025

Antegrade Medical Announces the Closing of a $7.3M Seed Financing

28 October 2025

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

All Articles

11 December 2025

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

28 October 2025

Antegrade Medical Announces the Closing of a $7.3M Seed Financing

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Sutter Health Hospitals Deploy Wearable Ultrasound Tech to Personalize Fluid Management for Sepsis

World’s First Wearable Doppler Ultrasound Patch Expands to East Coast to Enhance Patient Safety at The Mount Sinai Hospital

Genesys Capital is closing its largest fund to date – Genesys Ventures IV LP